Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Oncology·MeSH: Breast Neoplasms
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)?
BioSniper tracks 2 drugs in development for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) across 2 companies.
How many clinical trials target Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)?
There are 1 clinical trial targeting Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) tracked by BioSniper.
What is the prevalence of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)?
The estimated prevalence of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.
Deep-dive into Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis